- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Sight Sciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Mo | Earnings call: Sight Sciences reports modest Q1 revenue growth, eyes expansion | 1 | Investing.com | ||
| Fr | Sight Sciences Inc reports results for the quarter ended in March - Earnings Summary | - | Reuters | ||
| Fr | Sight Sciences GAAP EPS of $0.33, revenue of $19.3M | 1 | Seeking Alpha | ||
| 29.04. | Sight Sciences to earn $34M from Alcon patent infringement suit | 8 | MassDevice | ||
| 29.04. | Sight Sciences Reports $34 Mln Patent Infringement Verdict Against Alcon | 2 | RTTNews | ||
| 29.04. | Sight Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.04. | Sight Sciences, Inc.: Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery | 3 | GlobeNewswire (USA) | ||
| 18.04. | Sight Sciences, Inc.: Sight Sciences to Report First Quarter Financial Results on May 2, 2024 | 1 | GlobeNewswire (USA) | ||
| 12.04. | Sight Sciences, Inc.: Sight Sciences gibt die Veröffentlichung einer groß angelegten, praxisnahen MIGS-Studie als Nachweis für die Wirksamkeit des umfassenden Verfahrens zur Wiederherstellung des Kammerwasserabflusses mit der OMNI® Surgical System-Technol | 153 | GlobeNewswire (Deutschland) | Die Wirksamkeit der drei am häufigsten verwendeten MIGS-Technologien in Kombination mit einer Kataraktoperation und der Kataraktoperation allein wurde an über 100.000 Augen von Glaukompatienten untersucht... ► Artikel lesen | |
| 10.04. | Sight Sciences, Inc.: Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Redu | 280 | GlobeNewswire (Europe) | The efficacy of the three most commonly used MIGS technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyesMENLO... ► Artikel lesen | |
| 02.04. | Sight Sciences, Inc.: Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting | 64 | GlobeNewswire (Europe) | Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of TearCare® technology as a primary treatment for dry eye disease. MENLO... ► Artikel lesen | |
| 26.03. | Sight Sciences, Inc.: Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 08.03. | Sight Sciences, Inc. (SGHT) Q4 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
| 08.03. | Earnings call: Sight Sciences projects growth amid Q4 revenue dip | 1 | Investing.com | ||
| 08.03. | Sight Sciences Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 07.03. | Sight Sciences: Q4 Earnings Insights | 1 | Benzinga.com | ||
| 07.03. | Sight Sciences GAAP EPS of -$0.22 beats by $0.12, revenue of $18.8M misses by $0.6M | 1 | Seeking Alpha | ||
| 07.03. | Sight Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.03. | Sight Sciences, Inc.: Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance | 44 | GlobeNewswire (Europe) | MENLO PARK, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORPEA | 13,954 | -0,60 % | ORPEA S.A.: Filing of the 2023 Universal Registration Document | Regulatory News:
ORPEA S.A. (the "Company") (Paris:ORP) filed, today, its 2023 Universal Registration Document (document d'enregistrement universel) with the French Autorité des Marchés Financiers... ► Artikel lesen | |
| NANO-X IMAGING | 9,450 | 0,00 % | Nano-X Imaging LTD.: Nanox Announces AI Software Increases Identification of Patients with Vertebral Compression Fractures, an early sign of Osteoporosis, Up to Six-Fold | - According to early findings in the ADOPT study, Nanox.AI software improves detection of key risk factor for osteoporosis, outperforming UK National Health Service national average - Findings... ► Artikel lesen | |
| BUTTERFLY NETWORK | 0,970 | 0,00 % | Butterfly Network Reports First Quarter 2024 Financial Results | BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with handheld, whole-body ultrasound... ► Artikel lesen | |
| GOODRX | 7,470 | 0,00 % | GoodRx Reports Fourth Quarter and Full Year 2023 Results | SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., has released its financial... ► Artikel lesen | |
| JOINT CORP | 15,790 | -2,05 % | Earnings call: The Joint Corp. sees 9% sales increase, boosts EBITDA | ||
| CARMAT | 3,640 | +7,69 % | CARMAT Continues to Build on Its Momentum in the EFICAS Study and Reiterates Confidence in Its 2024 Outlook | EFICAS study reaches the milestone of 20 implants
Interim study results above expectations
Confirmation of short-term financial support from several key shareholders
Regulatory... ► Artikel lesen | |
| HYPERFINE | 0,830 | 0,00 % | Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
| MIMEDX | 7,140 | -3,12 % | MiMedx Group, Inc: MIMEDX Announces First Quarter 2024 Operating and Financial Results | Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management... ► Artikel lesen | |
| BIOMERICA | 0,588 | 0,00 % | Biomerica, Inc.: Biomerica Reports Third Quarter 2024 Financial Results | Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented... ► Artikel lesen | |
| ATRION | 402,00 | 0,00 % | Dividendenbekanntmachungen (14.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PLC GB00BF8Q6K64 0,073 GBP 0,0853 EUR ABRDN PLC ADR US00108N1000 0,3203 USD 0,2925 EUR ACCO BRANDS CORPORATION US00081T1088 0... ► Artikel lesen | |
| ATRICURE | 22,100 | +5,79 % | AtriCure Reports First Quarter 2024 Financial Results | MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and... ► Artikel lesen | |
| TALKSPACE | 3,180 | 0,00 % | Talkspace Q1 Earnings Preview | ||
| CASTLE BIOSCIENCES | 24,410 | +0,33 % | Castle Biosciences Reports First Quarter 2024 Results | FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results... ► Artikel lesen | |
| AMWELL | 0,581 | 0,00 % | Amwell bullish on strong growth from defense contract in 2024 despite declining revenue in Q1 |
SIGHT SCIENCES INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 5,820 Euro und damit -2,35 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
